Trial · NCT06907199
Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections
NCT06907199, Phase 1, Recruiting, University of Texas Southwestern Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections. Trials, record NCT06907199. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06907199
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections
- NCT number
- NCT06907199
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 104 participants, estimated
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Recurrent UTIs, Cystitis Recurrent
- Interventions
- Electrofulguration (EF), Nitrofurantoin (NF)
- First posted
- 2025-04-02
- Last updated
- 2026-07-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment of cystitis with NF vs EF+NF | Baseline to 30 months after enrollment to completion of study | Rate of culture documented symptomatic UTIs following the completion of each 6-month study arm intervention. Specifically, from 6 to 18 months (first year) after the completion of the original intervention and, 18 to 30 months (second year). |
| Secondary | No recurring cystitis | Baseline to 30 months after enrollment to completion of study | Comparison of patient characteristics between the two enrolling institutions. |
| Secondary | Rate comparison of culture-documented breakthrough | Baseline to 30 months after enrollment to completion of study | Rate of culture-documented breakthrough UTIs between the two treatment arms. |
| Secondary | Rate of multi-drug resistant organisms | Baseline to 30 months after enrollment to completion of study | Rate of urine cultures showing multi-drug resistant organisms in each treatment arm. |
| Secondary | Rate of non-urine culture | Baseline to 30 months after enrollment to completion of study | Rate of non-urine culture documented symptomatic UTI episodes for 12 months and 24 months following end of treatment arms, as determined by the Urinary Tract Infection Symptom Assessment (UTISA) (a total score of 3 or higher, or any individual score of 2 or 3) between the two treatment arms. |
| Secondary | Rate of behavior changes | Baseline to 30 months after enrollment to completion of study | Rate of behavior changes in both groups (fluid increases or use of non-antibiotic therapies, e.g., cranberry, D-mannose, urinary analgesics, hormonal therapy) in each treatment arm. |
| Secondary | Rate of score differences in symptoms and quality of life | Baseline to 30 months after enrollment to completion of study | Rate of score differences in patient symptoms and quality of life assessments using validated questionnaires- the Urinary Tract Infection Symptom Assessment (UTISA), Urinary Distress Inventory, Short Form (UDI-6), and Quality of Life scale (QoL) by Visual Analogue Scale (VAS) between both treatment arms. |
| Secondary | Rate of UTI episodes | Baseline to 30 months after enrollment to completion of study | Rate of UTI episodes (after first and second year of the completion of the intervention) compared to the rate of UTI episodes prior to the start of study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK140224 | A multi-centric randomized trial of daily nitrofurantoin versus bladder fulguration plus daily nitrofurantoin for the long-term management of cystitis in women with recurrent urinary tract infections | ZIMMERN, PHILIPPE E | UT SOUTHWESTERN MEDICAL CENTER | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06907199
GET https://conductscience.org/api/trials/v1/NCT06907199/registered